Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C225-ILs-dox
- Development stage
- Unknown
- Lead developer
- University Hospital Basel
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
C225-ILs-dox (anti-EGFR immunoliposomes loaded with doxorubicin) is an experimental targeted nanomedicine developed by the University Hospital Basel for the treatment of relapsed or refractory EGFR-amplified glioblastoma and high-grade gliomas. The drug consists of pegylated liposomal doxorubicin (derived from Caelyx) covalently conjugated to the Fab' fragments of the anti-EGFR monoclonal antibody cetuximab (C225). This design allows for the targeted delivery of the cytotoxic payload, doxorubicin, specifically to tumor cells overexpressing the epidermal growth factor receptor (EGFR), potentially increasing intratumoral drug concentration while minimizing systemic toxicity. It has been evaluated in a Phase 1 pharmacokinetic study known as the GBM-LIPO trial (NCT03603379).
- Other names
- anti-EGFR immunoliposomes loaded with doxorubicincetuximab-immunoliposomal doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)EGFR T790M (Epidermal growth factor receptor T790M mutant)DNA
Beyond the preview
Go deeper on C225-ILs-dox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C225-ILs-dox.